Peptide Aggregation: Why It Happens and How to Prevent It
Aggregation is the failure mode that leaves no visible trace. What drives it, which sequences are at risk, and the handling rules that actually prevent it.
Aggregation is the failure mode that does not announce itself. A peptide that has aggregated may look identical in the vial, pass a visual inspection, and produce results that are simply wrong — lower activity, higher variance, and no obvious cause.
What aggregation is
A peptide in solution holds a specific three-dimensional shape maintained by weak forces: hydrogen bonds, hydrophobic packing, electrostatic attraction. None of them are covalent. Aggregation is what happens when molecules start associating with each other instead of staying separate — hydrophobic faces that should be tucked inward find each other, and the assembly grows.
The process is usually irreversible. Once a peptide has formed an ordered aggregate, diluting the solution does not take it apart.
What drives it
- Air–liquid interfaces. The single most underappreciated cause. At the surface between liquid and air, peptides unfold — the interface is hydrophobic, and exposing a hydrophobic face there is energetically favourable. Every bubble creates surface area. This is the mechanism behind “swirl, do not shake”, and it is not fussiness.
- Freeze–thaw cycling. As water freezes it forms pure ice crystals and everything dissolved is pushed into the shrinking liquid fraction, where local concentration rises sharply. Each cycle compounds the damage.
- Concentration. Aggregation is concentration-dependent, and often steeply so. A peptide stable at 1 mg/ml may not be at 10.
- Temperature. Higher temperature increases molecular motion and the rate at which molecules encounter each other.
- pH near the isoelectric point. At the pH where a peptide carries no net charge, the electrostatic repulsion that keeps molecules apart disappears. Solubility is usually at its minimum there.
Which sequences are at risk
Hydrophobic residues are the main predictor. A sequence with runs of isoleucine, leucine, valine, phenylalanine or tryptophan has more hydrophobic surface to hide, and more reason to hide it against another molecule. Length contributes — more residues means more ways to misfold — and beta-sheet-forming sequences are the classic case.
A short, highly charged peptide like KPV is at the low-risk end. A long hydrophobic sequence is at the other.
Prevention, in order of effect
- Never shake. Swirl, or let it stand. Vortexing a peptide solution is the fastest way to aggregate it.
- Direct solvent down the vial wall rather than jetting it onto the lyophilisate. A stream hitting the cake creates both shear and bubbles.
- Aliquot instead of freeze–thawing. If a solution will be frozen, divide it first so no portion thaws more than once.
- Do not over-concentrate. Choosing a solvent volume for convenience can put you above the stability threshold.
- Minimise headspace and time open. Less air contact, less interface.
- Keep it cold once dissolved — 2 to 8 °C.
Detecting it
Visible cloudiness or particulates mean aggregation has gone far enough to scatter light, which is late. Earlier detection needs instrumentation: dynamic light scattering, size-exclusion chromatography, or a UV absorbance ratio.
The practical implication for most work is that a clear solution is not evidence of an intact one. Handling discipline is what protects the material, because inspection will not tell you in time.
Our storage and stability notes cover the other degradation routes, and the reconstitution guide covers technique. Every batch we supply is analysed by an independent laboratory for HPLC purity and mass-spectrometric identity, with batch-matched certificates available on request.
All products and information referenced are for in-vitro research and laboratory use only. Nothing here is medical advice, and no therapeutic claim is made or implied.